477 related articles for article (PubMed ID: 21821697)
1. Pharmacological characterization of 2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine (PF-04455242), a high-affinity antagonist selective for κ-opioid receptors.
Grimwood S; Lu Y; Schmidt AW; Vanase-Frawley MA; Sawant-Basak A; Miller E; McLean S; Freeman J; Wong S; McLaughlin JP; Verhoest PR
J Pharmacol Exp Ther; 2011 Nov; 339(2):555-66. PubMed ID: 21821697
[TBL] [Abstract][Full Text] [Related]
2. Design and discovery of a selective small molecule κ opioid antagonist (2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine, PF-4455242).
Verhoest PR; Basak AS; Parikh V; Hayward M; Kauffman GW; Paradis V; McHardy SF; McLean S; Grimwood S; Schmidt AW; Vanase-Frawley M; Freeman J; Van Deusen J; Cox L; Wong D; Liras S
J Med Chem; 2011 Aug; 54(16):5868-77. PubMed ID: 21744827
[TBL] [Abstract][Full Text] [Related]
3. LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders.
Rorick-Kehn LM; Witkin JM; Statnick MA; Eberle EL; McKinzie JH; Kahl SD; Forster BM; Wong CJ; Li X; Crile RS; Shaw DB; Sahr AE; Adams BL; Quimby SJ; Diaz N; Jimenez A; Pedregal C; Mitch CH; Knopp KL; Anderson WH; Cramer JW; McKinzie DL
Neuropharmacology; 2014 Feb; 77():131-44. PubMed ID: 24071566
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of novel kappa opioid receptor antagonists on dopamine neurons using acute brain slice electrophysiology.
Margolis EB; Wallace TL; Van Orden LJ; Martin WJ
PLoS One; 2020; 15(12):e0232864. PubMed ID: 33373369
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the agonist PET radioligand [¹¹C]GR103545 to image kappa opioid receptor in humans: kinetic model selection, test-retest reproducibility and receptor occupancy by the antagonist PF-04455242.
Naganawa M; Jacobsen LK; Zheng MQ; Lin SF; Banerjee A; Byon W; Weinzimmer D; Tomasi G; Nabulsi N; Grimwood S; Badura LL; Carson RE; McCarthy TJ; Huang Y
Neuroimage; 2014 Oct; 99():69-79. PubMed ID: 24844744
[TBL] [Abstract][Full Text] [Related]
6. Identification of an opioid kappa receptor subtype-selective N-substituent for (+)-(3R,4R)-dimethyl-4-(3-hydroxyphenyl)piperidine.
Thomas JB; Fall MJ; Cooper JB; Rothman RB; Mascarella SW; Xu H; Partilla JS; Dersch CM; McCullough KB; Cantrell BE; Zimmerman DM; Carroll FI
J Med Chem; 1998 Dec; 41(26):5188-97. PubMed ID: 9857089
[TBL] [Abstract][Full Text] [Related]
7. A role for kappa-, but not mu-opioid, receptor activation in acute food deprivation-induced reinstatement of heroin seeking in rats.
Sedki F; Eigenmann K; Gelinas J; Schouela N; Courchesne S; Shalev U
Addict Biol; 2015 May; 20(3):423-32. PubMed ID: 24725195
[TBL] [Abstract][Full Text] [Related]
8. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
Baker AK; Meert TF
J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
[TBL] [Abstract][Full Text] [Related]
9. Antidepressant-like effects of kappa-opioid receptor antagonists in the forced swim test in rats.
Mague SD; Pliakas AM; Todtenkopf MS; Tomasiewicz HC; Zhang Y; Stevens WC; Jones RM; Portoghese PS; Carlezon WA
J Pharmacol Exp Ther; 2003 Apr; 305(1):323-30. PubMed ID: 12649385
[TBL] [Abstract][Full Text] [Related]
10. Regulation of ingestive behaviors in the rat by GSK1521498, a novel micro-opioid receptor-selective inverse agonist.
Ignar DM; Goetz AS; Noble KN; Carballo LH; Stroup AE; Fisher JC; Boucheron JA; Brainard TA; Larkin AL; Epperly AH; Shearer TW; Sorensen SD; Speake JD; Hommel JD
J Pharmacol Exp Ther; 2011 Oct; 339(1):24-34. PubMed ID: 21712426
[TBL] [Abstract][Full Text] [Related]
11. Quantitative PK-PD model-based translational pharmacology of a novel kappa opioid receptor antagonist between rats and humans.
Chang C; Byon W; Lu Y; Jacobsen LK; Badura LL; Sawant-Basak A; Miller E; Liu J; Grimwood S; Wang EQ; Maurer TS
AAPS J; 2011 Dec; 13(4):565-75. PubMed ID: 21847689
[TBL] [Abstract][Full Text] [Related]
12. Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.
Broadbear JH; Sumpter TL; Burke TF; Husbands SM; Lewis JW; Woods JH; Traynor JR
J Pharmacol Exp Ther; 2000 Sep; 294(3):933-40. PubMed ID: 10945843
[TBL] [Abstract][Full Text] [Related]
13. Probes for narcotic receptor-mediated phenomena. 25. Synthesis and evaluation of N-alkyl-substituted (alpha-piperazinylbenzyl)benzamides as novel, highly selective delta opioid receptor agonists.
Katsura Y; Zhang X; Homma K; Rice KC; Calderon SN; Rothman RB; Yamamura HI; Davis P; Flippen-Anderson JL; Xu H; Becketts K; Foltz EJ; Porreca F
J Med Chem; 1997 Aug; 40(18):2936-47. PubMed ID: 9288176
[TBL] [Abstract][Full Text] [Related]
14. LPK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential.
Tao YM; Li QL; Zhang CF; Xu XJ; Chen J; Ju YW; Chi ZQ; Long YQ; Liu JG
Eur J Pharmacol; 2008 Apr; 584(2-3):306-11. PubMed ID: 18353307
[TBL] [Abstract][Full Text] [Related]
15. (2S,3R) beta-methyl-2',6'-dimethyltyrosine-L-tetrahydroisoquinoline-3-carboxylic acid [(2S,3R)TMT-L-Tic-OH] is a potent, selective delta-opioid receptor antagonist in mouse brain.
Hosohata K; Varga EV; Alfaro-Lopez J; Tang X; Vanderah TW; Porreca F; Hruby VJ; Roeske WR; Yamamura HI
J Pharmacol Exp Ther; 2003 Feb; 304(2):683-8. PubMed ID: 12538822
[TBL] [Abstract][Full Text] [Related]
16. Discovery of aminobenzyloxyarylamides as κ opioid receptor selective antagonists: application to preclinical development of a κ opioid receptor antagonist receptor occupancy tracer.
Mitch CH; Quimby SJ; Diaz N; Pedregal C; de la Torre MG; Jimenez A; Shi Q; Canada EJ; Kahl SD; Statnick MA; McKinzie DL; Benesh DR; Rash KS; Barth VN
J Med Chem; 2011 Dec; 54(23):8000-12. PubMed ID: 21958337
[TBL] [Abstract][Full Text] [Related]
17. Comparison of [Dmt1]DALDA and DAMGO in binding and G protein activation at mu, delta, and kappa opioid receptors.
Zhao GM; Qian X; Schiller PW; Szeto HH
J Pharmacol Exp Ther; 2003 Dec; 307(3):947-54. PubMed ID: 14534366
[TBL] [Abstract][Full Text] [Related]
18. Pharmacological properties of JDTic: a novel kappa-opioid receptor antagonist.
Carroll I; Thomas JB; Dykstra LA; Granger AL; Allen RM; Howard JL; Pollard GT; Aceto MD; Harris LS
Eur J Pharmacol; 2004 Oct; 501(1-3):111-9. PubMed ID: 15464069
[TBL] [Abstract][Full Text] [Related]
19. Transient overexpression of kappa and mu opioid receptors using recombinant adenovirus vectors.
Zhen Z; Bradel-Tretheway BG; Dewhurst S; Bidlack JM
J Neurosci Methods; 2004 Jul; 136(2):133-9. PubMed ID: 15183265
[TBL] [Abstract][Full Text] [Related]
20. Use of the mouse vas deferens to determine mu, delta, and kappa receptor affinities of opioid antagonists.
Cohen ML; Mendelsohn LG; Mitch CH; Zimmerman DM
Receptor; 1994; 4(1):43-53. PubMed ID: 8038706
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
